Literature DB >> 21848538

Gal/non-Gal antigens in pig tissues and human non-Gal antibodies in the GalT-KO era.

Michael E Breimer1.   

Abstract

Our knowledge regarding Gal and non-Gal antigens in GalT-KO pig tissues can be summarized as α3Galactosyl-tranferase gene knock out eliminates the Galα3Galβ4GlcNAc-R antigen expression in pig tissues as well as anti-Gal antibody binding. Other Galα-terminating saccharides (e.g. iGb3 glycolipids and Galα2 determinants) may be present but have not been documented. α3Galactosyl-tranferase gene knock out slightly changes the carbohydrate antigen expression but no "new" antigens recognized by the human immune system have been found. Non-Gal antigens are both of protein and carbohydrate nature but their exact chemical structures are poorly defined. Regarding human non-Gal antibodies our knowledge is as Non-Gal antibodies exist naturally and increase in humans/non-human primate (NHP) receiving WT or GalT-KO pig grafts. Non-Gal antibodies with new antigen epitope recognition can be induced in humans/NHP after challenge by WT or GalT-KO pig grafts. Non-Gal antibodies react with both carbohydrates and proteins. Part of the protein reactivity is directed to glycoprotein carbohydrates chains. Non-Gal antibodies reacting with neuraminic acid terminated saccharides (both N-Acetyl and N-Glycoloyl variants) are present in humans/NHP. Anti-neuraminic acid antibodies are increased, as well as induced, after grafting pig organs into humans/NHP. Non-Gal antibodies does not cause hyperacute xenorejection but can be cytotoxic and cause xenoorgan damage. If humans sensitized to HLA antigens are at a higher risk of rejecting pig xenograft compared with non-sensitized individuals is not fully clarified. Clinical trials are needed to evaluate the relevance of non-Gal antigens/antibodies and for the xenofield to advance.
© 2011 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21848538     DOI: 10.1111/j.1399-3089.2011.00644.x

Source DB:  PubMed          Journal:  Xenotransplantation        ISSN: 0908-665X            Impact factor:   3.907


  20 in total

1.  Is there a correlation between anti-pig antibody levels in humans and geographic location during childhood?

Authors:  Goutham Kumar; Vikas Satyananda; Jason Fang; Hao Zhou; Minoru Fujita; Burcin Ekser; Cassandra Long; Eefje Dons; Qing Sun; David Ayares; Hidetaka Hara; David K C Cooper
Journal:  Transplantation       Date:  2013-08-27       Impact factor: 4.939

2.  Anti-non-Gal-specific combination treatment with an anti-idiotypic Ab and an inhibitory small molecule mitigates the xenoantibody response.

Authors:  John M Stewart; Alice F Tarantal; Yan Chen; Nancy C Appleby; Tania I Fuentes; C Chang I Lee; Evelyn J Salvaris; Anthony J F d'Apice; Peter J Cowan; Mary Kearns-Jonker
Journal:  Xenotransplantation       Date:  2014-03-17       Impact factor: 3.907

Review 3.  Immunological challenges and therapies in xenotransplantation.

Authors:  Marta Vadori; Emanuele Cozzi
Journal:  Cold Spring Harb Perspect Med       Date:  2014-04-01       Impact factor: 6.915

Review 4.  Clinical lung xenotransplantation--what donor genetic modifications may be necessary?

Authors:  David K C Cooper; Burcin Ekser; Christopher Burlak; Mohamed Ezzelarab; Hidetaka Hara; Leela Paris; A Joseph Tector; Carol Phelps; Agnes M Azimzadeh; David Ayares; Simon C Robson; Richard N Pierson
Journal:  Xenotransplantation       Date:  2012 May-Jun       Impact factor: 3.907

5.  Rhesus monkeys and baboons develop clotting factor VIII inhibitors in response to porcine endothelial cells or islets.

Authors:  John M Stewart; Alice F Tarantal; Wayne J Hawthorne; Evelyn J Salvaris; Philip J O'Connell; Mark B Nottle; Anthony J F d'Apice; Peter J Cowan; Mary Kearns-Jonker
Journal:  Xenotransplantation       Date:  2014-05-08       Impact factor: 3.907

6.  Development of a consensus protocol to quantify primate anti-non-Gal xenoreactive antibodies using pig aortic endothelial cells.

Authors:  Agnes M Azimzadeh; Guerard W Byrne; Mohamed Ezzelarab; Emily Welty; Gheorghe Braileanu; Xiangfei Cheng; Simon C Robson; Christopher G A McGregor; David K C Cooper; Richard N Pierson
Journal:  Xenotransplantation       Date:  2014-09-01       Impact factor: 3.907

7.  Characterization of immunogenic Neu5Gc in bioprosthetic heart valves.

Authors:  Eliran Moshe Reuven; Shani Leviatan Ben-Arye; Tal Marshanski; Michael E Breimer; Hai Yu; Imen Fellah-Hebia; Jean-Christian Roussel; Cristina Costa; Manuel Galiñanes; Rafael Mañez; Thierry Le Tourneau; Jean-Paul Soulillou; Emanuele Cozzi; Xi Chen; Vered Padler-Karavani
Journal:  Xenotransplantation       Date:  2016-09-09       Impact factor: 3.907

8.  Structural complexity of non-acid glycosphingolipids in human embryonic stem cells grown under feeder-free conditions.

Authors:  Angela Barone; John Benktander; Jonas Ångström; Anders Aspegren; Petter Björquist; Susann Teneberg; Michael E Breimer
Journal:  J Biol Chem       Date:  2013-02-12       Impact factor: 5.157

9.  Transplantable liver production plan: "Yamaton"--liver project, Japan.

Authors:  Toshiyuki Hata; Shinji Uemoto; Eiji Kobayashi
Journal:  Organogenesis       Date:  2013-07-29       Impact factor: 2.500

Review 10.  Xenotransplantation: immunological hurdles and progress toward tolerance.

Authors:  Adam Griesemer; Kazuhiko Yamada; Megan Sykes
Journal:  Immunol Rev       Date:  2014-03       Impact factor: 12.988

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.